Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CTSA | P10619 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963773 | 0.87 | SMPD1 (0.33) | LAP3SMPD1FDPSBLMTDP1 | |
| SCHEMBL16688120 | 0.82 | LAP3 (0.38) | LAP3CA2CA12CA1MMP1 | |
| SCHEMBL12960884 | 0.77 | LAP3 (0.38) | LAP3SMPD1FDPSBLMTDP1 | |
| SCHEMBL2475819 | 0.77 | LAP3 (0.38) | LAP3SMPD1FDPSBLMTDP1 | |
| SCHEMBL3898905 | 0.76 | SMPD1 (0.42) | LAP3SMPD1FDPSBLMTDP1 | |
| SCHEMBL5671571 | 0.75 | CTSA (0.36) | CTSAACHE | |
| Phosphorylisopropane SCHEMBL82996 | 0.75 | — | — | |
| SCHEMBL10447789 | 0.75 | SMPD1 (0.39) | LAP3SMPD1FDPSBLMTDP1 | |
| SCHEMBL5963622 | 0.75 | SMPD1 (0.39) | LAP3SMPD1FDPSBLMTDP1 | |
| SCHEMBL31316283 | 0.74 | LAP3 (0.36) | LAP3SMPD1FDPSBLMTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116745025-A | membrane for water filtration | 水通道蛋白有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | ONO PHARMACEUTICAL CO., LTD. (JP) | 2023-05-11 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-10036838-B2 | Infrared ray absorbing composition or infrared ray absorbing composition kit, infrared ray cut filter using the same, method for producing the infrared ray cut filter, camera module, and method for producing the camera module | FUJIFILM CORPORATION (JP) | 2018-07-31 | — | — | US | disclosed |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-17 | — | — | US | disclosed |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-07-03 | — | — | US | disclosed |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-9810821-B2 | Infrared ray cutoff filter | FUJIFILM CORPORATION (JP) | 2017-11-07 | — | — | US | disclosed |
| US-6905031-B1 | Solid phase microextraction device using aerogel | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-06-14 | — | — | US | disclosed |
| US-20050044778-A1 | Fuel compositions employing catalyst combustion structure | OCTANE INTERNATIONAL, LTD. | 2005-03-03 | — | — | US | disclosed |
| US-20040237384-A1 | Fuel compositions exhibiting improved fuel stability | OCTANE INTERNATIONAL, LTD. | 2004-12-02 | — | — | US | disclosed |
| US-6652608-B1 | Fuel compositions exhibiting improved fuel stability | OCTANE INTERNATIONAL, LTD. | 2003-11-25 | — | — | US | disclosed |
| US-20030022389-A1 | Chemical specific adsorption aerogel for sample collection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2003-01-30 | — | — | US | disclosed |
| EP-0954558-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR, William C. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1998026028-A1 | FUEL COMPOSITIONS EXHIBITING IMPROVED FUEL STABILITY | ORR WILLIAM C (US) | 1998-06-18 | — | — | WO | disclosed |
| US-4433975-A | HETEROCYCLIC QUATERNARY AMMONIUM PHOSPHATES | CIBA-GEIGY CORPORATION (US) | 1984-02-28 | — | — | US | disclosed |
| US-4432886-A | 2-FURANYLBENZIMIDAZOLE, OR 2-AZOLYLBENZIMIDAZOLE, OR 2-STILBENYLBENZIMIDAZOLE, OR 2,5-(BENZIMIDAZOLYL)FURAN PHOSPHATES | CIBA-GEIGY CORPORATION (US) | 1984-02-21 | — | — | US | disclosed |
| US-4384121-A | WATER SOLUBLE | CIBA-GEIGY CORPORATION (US) | 1983-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141284-A1 | CANCER THERAPEUTIC METHOD | STING1, CGAS, IFNAR1 | LAP3 2792/4885SMPD1 625/4885FDPS 2926/4885 |
| US-10011569-B2 | Process for synthesizing oxidized lactam compounds | COASY, DHPS, OXA1L | LAP3 2828/4885SMPD1 2708/4885FDPS 29/4885 |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | LAP3 3745/4885SMPD1 2207/4885FDPS 494/4885 |
| US-10023537-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | LAP3 3745/4885SMPD1 2207/4885FDPS 494/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | LAP3 114/4885SMPD1 327/4885FDPS 809/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | LAP3 3745/4885SMPD1 2207/4885FDPS 494/4885 |
| US-20230151024-A1 | STING AGONISTIC COMPOUND | STING1, CGAS, TLR1 | LAP3 2896/4885SMPD1 274/4885FDPS 2443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.